CYBERDYNE Inc. (7779) Stock Price

CYBERDYNE develops businesses using cybernics technology to address social challenges in an aging society with declining birth rates. This technology integrates humans with AI robots and AI information systems, aiming to build a future society called "Technopia Support Society" where technology and people coexist.

CYBERDYNE's business consists primarily of research and development, manufacturing, and sales of products utilizing cybernics technology, as well as provision of treatment and training services, and startup support to foster the cybernics industry. These efforts realize improved independence for patients and elderly people, prevention and early detection, daily living support, and work support.

HAL®, CYBERDYNE's core technology, operates using weak bioelectric signals that reflect the wearer's motor intention from the nervous system. This allows HAL® to be driven based on the wearer's movement intention, supporting body movement. HAL® is characterized by hybrid control combining cybernetic voluntary control, autonomous control, and impedance control.

CYBERDYNE deploys cybernics therapy using HAL® in the medical field, promoting functional improvement of the brain, nervous system, and muscles. In the care and independence support field, CYBERDYNE offers various types of HAL® designed to improve independence and prevent frailty in elderly people. In the work support field, CYBERDYNE deploys HAL® and AI-equipped robots to prevent lower back pain risk.

Additionally, CYBERDYNE provides the photoacoustic imaging device "Acoustic X" as a research instrument for prevention and early detection. This device achieves non-invasive, high-resolution 3D imaging and is advancing toward medical device approval. CYBERDYNE's business is operated as a single segment in robot-related business.

CYBERDYNE aims to solve social challenges by leveraging cybernics technology. This technology integrates humans, AI robots, and AI information systems to build a future society called "Techno Pia Support Society." CYBERDYNE is opening new markets through the creation of innovative technologies and new industries while promoting talent development.

As a research and development-focused company, CYBERDYNE advances innovative product development and clinical/demonstration research. In particular, the number of HAL® units in operation serves as a key non-financial indicator for sustainable growth. Revenue from HAL® rental and maintenance contracts is expected to provide a continuous revenue stream.

CYBERDYNE is advancing clinical trials to establish cybernics therapy as a global standard treatment. In Japan, HAL® medical lower-limb type has been approved for neurological and muscular diseases, with ongoing expansion of indications. Indication expansions are also progressing in Germany and the United States.

CYBERDYNE is expanding cybernics technology globally and obtaining medical device approvals in various countries. In addition to indication expansions in Western markets and APAC countries, the company is promoting overseas deployment of products such as Cyvis®. It is strengthening international partnerships to advance the adoption of cybernics technology.

CYBERDYNE is also focusing on strengthening consumer products and services. Through the NeuroHALFIT® program, it supports physical function improvement and frailty prevention. The company is also deploying the Cyvis® series for home and workplace use to support health management.

CYBERDYNE is strengthening its business promotion structure and developing future-oriented talent. It provides innovative solutions based on cybernics technology to address social challenges across multiple domains, accelerating global expansion through organizational strengthening and talent development.